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ADAMTSMembrane microvesicle shedding is an active process and occurs in viable cells with no signs of apoptosis or
necrosis. We report here that microvesicles shed by oligodendroglioma cells contain an ‘aggrecanase’ activity,
cleaving aggrecan at sites previously identiﬁed as targets for adamalysin metalloproteinases with disintegrin
and thrombospondin domains (ADAMTSs). Degradation was inhibited by EDTA, the metalloproteinase inhib-
itor GM6001 and by tissue inhibitor of metalloproteinases (TIMP)-3, but not by TIMP-1 or TIMP-2. This inhib-
itor proﬁle indicates that the shed microvesicles contain aggrecanolytic ADAMTS(s) or related TIMP-3-
sensitive metalloproteinase(s). The oligodendroglioma cells were shown to express the three most active
aggrecanases, namely Adamts1, Adamts4 and Adamts5, suggesting that one or more of these enzymes may
be responsible for the microvesicle activity. Microvesicles shed by rheumatoid synovial ﬁbroblasts similarly
degraded aggrecan in a TIMP-3-sensitive manner. Our ﬁndings raise the novel possibility that microvesicles
may assist oligodendroglioma and rheumatoid synovial ﬁbroblasts to invade through aggrecan-rich extracel-
lular matrices.
© 2012 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
An increasing number of cell types have been shown to shed
microvesicles (MVs) under both physiological and pathological con-
ditions. MVs have been demonstrated to contain a wide array of bio-
logical effector molecules, including proteins, lipids, DNA, microRNA
and mRNA, and since MVs can interact with other cells, they can
serve as a means of cell-to-cell communication (Mathivanan et al.,
2010). MVs can interact with other cells either through direct mem-
brane fusion, or by utilising adhesion molecules such as L1
(Gutwein et al., 2005) and CD44 (Stoeck et al., 2006), or signalling
molecules such as integrins (Dolo et al., 1998; Taraboletti et al.,
2002) located on the MV surface. MVs can initiate various biological
events in target cells, ranging from apoptosis (D'Agostino et al.,
2006; Lo Cicero et al., 2011) to cell survival and proliferation
(Deregibus et al., 2007; Skog et al., 2008). They have also been
shown to mediate horizontal mRNA transfer (Deregibus et al., 2007;
Skog et al., 2008).ntegrin and metalloproteinase
; MEF, mouse embryonic ﬁbro-
cles; RA, rheumatoid arthritis;
: +44 20 8383 4999.
Troeberg).
-NC-ND license.Fibroblasts (Lee et al., 1993), reticulocytes (Johnstone et al., 1987),
endothelial cells (Taraboletti et al., 2002), lymphocytes (Raposo et al.,
1996), dendritic cells (Zitvogel et al., 1998) and platelets (Heijnen et
al., 1999), as well as by numerous cancer cell types (Ginestra et al.,
1997; Dolo et al., 1998) have been shown to shed MVs. The MV pop-
ulation can be subdivided into exosomes and shedding vesicles based
on their size and origin. Exosomes are 40–100 nm in diameter and are
derived from endosomal multivesicular bodies (Théry et al., 2002),
while shedding vesicles are 100–1000 nm in diameter and are gener-
ated by outward budding of the plasma membrane (Cocucci et al.,
2009). Cells commonly release both exosomes and shedding vesicles
into the extracellular space, with this mixed population referred to as
‘microvesicles’ (MVs).
MVs shed by tumour cells contain tumour antigens and can thus
contribute to immune system evasion (Andre et al., 2002). Tumour
MVs may also contribute to tumour invasion, as they contain
proteinases that degrade the ECM. For example, MVs have been dem-
onstrated to contain cathepsin B (Giusti et al., 2008), matrix metallo-
proteinase (MMP)-2 (Ginestra et al., 1997), MMP-9 (Ginestra et al.,
1997; Dolo et al., 1998), MT1-MMP (Taraboletti et al., 2002), and
urokinase-type plasminogen activator (Ginestra et al., 1997), as well
as the adamalysins ADAM10 (Gutwein et al., 2005; Stoeck et al.,
2006) and ADAM17 (Stoeck et al., 2006).
We have previously shown that G26/24 oligodendroglioma
cells shed MVs, which contain Fas ligand and tumour necrosis
factor α-related apoptosis-inducing ligand and induce apoptosis
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2011). In addition to their effects on healthy cells within the brain,
oligodendrogliomas remodel the brain extracellular matrix (ECM)
and invade into surrounding tissues (Bellail et al., 2004). Along
with other lecticans, aggrecan is a constituent of the brain ECM
(Yamaguchi, 2000; Bellail et al., 2004). In particular, aggrecan is
thought to be an important component of perineuronal nets
(Matthews et al., 2002), with its expression altered in pathological
conditions such as Alzheimer's disease (Morawski et al., 2010) and
early-life seizure (McRae et al., 2010).
Aggrecan is also a major constituent of the ECM of cartilage, and
aggrecan degradation is associated with progression of various
types of arthritis (Lohmander et al., 1993). During the development
of rheumatoid arthritis (RA), the cartilage matrix is invaded by
ﬁbroblasts originating from the synovial lining (Ospelt et al., 2004).
The invading synovial cells have been shown to express a number
of ECM-degrading MMPs (Murphy and Nagase, 2008) as well as
metalloproteinases with disintegrin and thrombospondin motifs
(ADAMTSs) (Yamanishi et al., 2002). ADAMTS-4 and ADAMTS-5 are
thought to be the primary ‘aggrecanases’ responsible for aggrecan
degradation in osteoarthritis (Murphy and Nagase, 2008).
Our results demonstrate for the ﬁrst time that MVs shed by both
oligodendroglioma cells and rheumatoid synovial ﬁbroblasts con-
tain a TIMP-3-sensitive aggrecanase activity. This suggests that
MVs may contribute to cellular invasion of aggrecan-rich extracellu-
lar matrices.Fig. 1. G26/24 MVs degrade aggrecan. (A) Aggrecan was incubated alone (−), or with reco
tibodies), or G26/24 MVs (4 μg) for 24 h at 37 °C and degradation products analysed by im
MVs (2 μg) at 37 °C for various times and formation of the 1772AGEG neo-epitope visualise
37 °C) and formation of the 1772AGEG neo-epitope visualised by immunoblotting.2. Results
2.1. G26/26 MVs cleave aggrecan at several sites
Using a panel of antibodies that recognise aggrecan degradation
products, we found that MVs shed by G26/24 oligodendroglioma
cells are able to degrade aggrecan at several sites.
Following incubation of 500 nM aggrecan with MVs (4 μg protein)
for 24 h at 37 °C, aggrecan degradation was visible using the 2-B-6
antibody (Caterson et al., 1985), which recognises chondroitinase-
treated aggrecan fragments (Fig. 1A). The pattern of the fragments
generated by 4 μg of G26/24MVsmirrored that obtained after incuba-
tion of aggrecan with 0.01 nM of recombinant ADAMTS-5.
Aggrecan degradation by G26/24 MVs was further investigated
using a panel of neoepitope antibodies that recognise aggrecan cleav-
age at sites previously shown to be hydrolysed by ADAMTS-4 and
ADAMTS-5 (Kashiwagi et al., 2004; Gendron et al., 2007; Troeberg
et al., 2008). Following 24 h of incubation at 37 °C with 4 μg of
MVs, aggrecan degradation was visible using anti-1772AGEG and
anti-GELE1480 antibodies, indicating that MVs cleaved aggrecan at
the TAQE1771–1772AGEG and GELE1480–1481GRGT sites in the chon-
droitin sulfate-rich region (Fig. 1A). The aggrecanase activity of MVs
was the same whether 0.05% Brij 35 was included in the assay buffer
or not. The degradation products were comparable with those gener-
ated by incubation of aggrecan with 0.01 nM recombinant ADAMTS-5
(Fig. 1A).mbinant ADAMTS-5 (5 nM for detection with anti-374ARGSV, 0.01 nM for all other an-
munoblotting with the indicated antibodies. (B) Aggrecan was incubated with G26/24
d by immunoblotting. (C) Aggrecan was incubated with G26/24 MVs (0.1–10 μg, 3 h,
Fig. 2. Aggrecan degradation by G26/24 MVs is due to a TIMP-3-sensitive metalloproteinase. G26/24 MVs (4 μg) or ADAMTS-5 (0.001 nM) were incubated alone (−) or with EDTA
(10 mM), TIMP-1 (100 nM), TIMP-2 (100 nM), GM6001 (5–100 μM) or N-TIMP-3 (5–100 nM) (1 h, 37 °C). Residual activity against aggrecan (3 h, 37 °C) was visualised using the
anti-1772AGEG neo-epitope antibody.
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interglobular domain was not detectable with an anti-374ARGSV
neoepitope antibody (Hughes et al., 1995) following incubation of
500 nM aggrecan with 4 μg of MVs for 24 h at 37 °C (Fig. 1A). Incuba-
tion of aggrecan with recombinant ADAMTS-5 (5 nM) generated the
expected cleavage product.
Aggrecan degradation by G26/24 MVs was shown to be time- and
dose-dependent. Using the anti-1772AGEG antibody, degradation of
aggrecan by 2 μg of MVs was linear for up to 4 h (Fig. 1B). Aggrecan
degradation was also dose-dependent, with formation of the
1772AGEG neoepitope increasing linearly over 3 h for 0.1 to 10 μg of
MVs (Fig. 1C).2.2. G26/26 MV aggrecan-degrading activity is inhibited by TIMP-3
We investigated the inhibitor sensitivity of the aggrecan-
degrading activity of G26/24 MVs by incubating MVs with various
proteinase inhibitors and measuring residual activity against the
TAQE1771–1772AGEG site.
The metal chelator EDTA (10 mM) blocked the formation of
the 1772AGEG neoepitope, indicating that a metalloproteinase
is responsible for degradation (Fig. 2). GM6001, a hydroxamate
metalloproteinase inhibitor, also inhibited aggrecan cleavage by
G26/24 MV, with GM6001 inhibiting activity completely at
100 μM and partially at 10 μM (Fig. 2).
TIMP-1 and TIMP-2 (100 nM) had no effect on aggrecan degrada-
tion by G26/24 MV, while N-TIMP-inhibited activity strongly and
similarly to N-TIMP-3 inhibition of ADAMTS-5. This inhibitory proﬁle
indicates that an ADAMTS or related TIMP-3-sensitive metalloprotei-
nase is responsible for the observed aggrecanase activity.Fig. 3. G26/24 cells express ADAMTS-1, ADAMTS-4 and ADAMTS-5. RT-PCR for
Adamts1, Adamt4 and Adamts5 was performed on total RNA isolated from G26/24
cells and MEF cells. Negative controls were performed without template.2.3. G26/26 cells express aggrecanolytic ADAMTSs
RT-PCR conﬁrmed the expression of Adamts1, Adamts4 and
Adamts5 by G26/24 cells (Fig. 3).
2.4. Rheumatoid synovial ﬁbroblast MVs cleave aggrecan in a
TIMP-3-sensitive manner
To investigate whether other cell types also shed MVs containing
aggrecan-degrading activity, we isolated MVs shed by primary
rheumatoid synovial ﬁbroblasts, normal skin ﬁbroblasts and HTB94
chondrosarcoma. The RA synovial ﬁbroblast MVs (4 μg of protein)
cleaved aggrecan at the TAQE1771–1772AGEG bond, while no activity
was detected with normal skin ﬁbroblast or HTB94 MVs (4 μg)
(Fig. 4A). Aggrecan degradation by RA ﬁbroblast MVs was inhibited
by 100 nM TIMP-3, indicating that this activity is also likely to be
due to an ADAMTS or related metalloproteinase.
3. Discussion
To our knowledge, this is the ﬁrst description of aggrecanase activ-
ity being present in microvesicles shed from two different cell types:
oligodendroglioma and rheumatoid synovial ﬁbroblasts. Based on our
inhibitor studies, the aggrecanase activity in the shed MVs is likely to
be due to ADAMTS metalloproteinase(s). ADAMTS-1, -4, -5, -8, -9, 15,
-16 and -18 have all been reported to degrade aggrecan (Murphy and
Nagase, 2008). Among these, ADAMTS-1 (Kuno et al., 2000),
ADAMTS-4 (Kashiwagi et al., 2004) and ADAMTS-5 (Gendron et al.,
2007) are the best characterised to date and show the strongest
aggrecanase activity. By RT-PCR, we conﬁrmed that G26/24 oligoden-
droglioma cells express all three of these enzymes, as previouslyFig. 4. RA synovial ﬁbroblast MVs degrade aggrecan. (A) Aggrecan was incubated
alone (−) or with MVs from G26/24 (4 or 1 μg), normal skin ﬁbroblasts (4 μg), RA sy-
novial ﬁbroblasts (4 μg) or HTB94 chondrosarcoma (4 μg) (24 h, 37 °C). Degradation
products were analysed by immunoblotting using an anti-1772AGEG neo-epitope
antibody. (B) MVs from G26/24 (4 μg) or RA synovial ﬁbroblasts (4 μg) were pre-
incubated with TIMP-3 (0–100 nM, 1 h, 37 °C) and residual activity against aggrecan
(24 h, 37 °C) visualised using an anti-1772AGEG neo-epitope antibody.
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blasts are known to express ADAMTS-4 and ADAMTS-5 (Yamanishi et
al., 2002). These enzymes are thus candidates for the aggrecanase ac-
tivity observed in the MVs. The MVs may contain a number of
ADAMTSs, including those whose expression has been conﬁrmed as
well as others that remain to be characterised. We were unable to
identify ADAMTSs present in the MVs by immunohistochemistry
due to the insensitivity of currently available antibodies. This limita-
tion, coupled with the low level at which the enzymes are expressed
in tissues, has hampered direct detection of aggrecanases in various
tissue samples.
G26/24 MVs cleaved aggrecan at two sites in the chondroitin
sulfate-rich region, namely at the TAQE1771–1772AGEG and
GELE1480–1481GRGT bonds. However, no cleavage of aggrecan at
the characteristic NITEGE373–374ARGSV aggrecanase site in the
interglobular region was detected. This may be because higher
concentrations of enzyme are required to detect cleavage at the
NITEGE373–374ARGSV site than at the TAQE1771–1772AGEG
and GELE1480–1481GRGT sites. For example, 5 nM recombinant
ADAMTS-5 was required to detect aggrecan cleavage using the
anti-374ARGSV antibody, while 0.01 nM ADAMTS-5 was sufﬁcient
to detect cleavage using the anti-1772AGEG and anti-GELE1480 anti-
bodies, in line with previous ﬁndings (Gendron et al., 2007). We
found that 4 μg of MVs from G26/26 cells cleaved aggrecan compa-
rably to 0.01 nM ADAMTS-5 at the TAQE1771–1772AGEG and
GELE1480–1481GRGT sites, suggesting that 2000 μg of MVs would be
required to detect activity at NITEGE373–374ARGSV. We were not
able to isolate sufﬁcient amounts of MVs to test this hypothesis.
Furthermore, we have found that heparin inhibits ADAMTS-4 hy-
drolysis of aggrecan, and that hydrolysis of the NITEGE373–374ARGSV
site is more sensitive to inhibition by heparin than the
GELE1480–1481GRGT site (Fushimi et al., 2008). Our data may thus
indicate that the aggrecan-degrading activity in G26/24 MVs has sim-
ilar properties and is associated with a heparan sulfate proteoglycan
on the surface of MVs. Membrane-associated aggrecanase activity
was ﬁrst described by Billington et al. in preparations of bovine
nasal chondrocyte membranes (Billington et al., 1998). ADAMTS-4 is
thought to associate with syndecan 1 on the surface of chondrosar-
coma cells (Gao et al., 2004), and ADAMTS-5 to associate with synde-
can 4 on chondrocytes (Echtermeyer et al., 2009). We thus postulate
that the aggrecanase activity is associated with the surface of the MVs
through interaction with heparan sulfate proteoglycans.
Both oligodendroglioma and rheumatoid synovial ﬁbroblasts are
capable of invading into brain and cartilage extracellular matrices,
which are rich in lectican chondroitin sulfate proteoglycans such as
aggrecan, versican, brevican and neurocan. Our ﬁndings suggest that
shed MVs may contribute to the ECM-degrading and invasive capaci-
ty of the cells. Degradation of brevican by ADAMTSs has been shown
to generate a cleaved fragment that increases the invasiveness of gli-
oma cells (Nakada et al., 2005), suggesting that aggrecanase activity
in shed MVs may also indirectly increase invasive capacity. The pres-
ence of ADAMTSs in shed MVs may represent a novel mechanism by
which cells target these enzymes to lectican substrates in diverse ex-
tracellular matrices.4. Experimental procedures
4.1. Materials
Human ADAMTS-5 lacking the C-terminal thrombospondin do-
main (Gendron et al., 2007), bovine aggrecan (Hascall and Sajdera,
1969), TIMP-1 (Troeberg et al., 2002), TIMP-2 (Troeberg et al.,
2002), TIMP-3 (Troeberg et al., 2009) and N-TIMP-3 (Kashiwagi et
al., 2001) were prepared as previously described. GM6001 was from
Elastin Products (Owensville, USA).4.2. Cell culture
Murine G26/24 oligodendroglioma and human HTB94 chondro-
sarcoma cells were maintained in DMEM supplemented with 10%
foetal calf serum, and 1% penicillin/streptomycin. Human synovial ﬁ-
broblasts were obtained with ethics approval and informed consent
from synovial tissue of RA patients undergoing joint replacement sur-
gery as previously described (Miller et al., 2009). Normal human skin
ﬁbroblasts were obtained with ethics approval and informed consent
from patients undergoing surgery for Dupuytren's disease as previ-
ously described (Verjee et al., 2009).
4.3. Preparation of MVs from conditioned medium
MVs were prepared from media conditioned for 24 h on subcon-
ﬂuent cells. Media were centrifuged at 2000 g (15 min, 4 °C) and
4000 g (15 min, 4 °C) to remove debris. MVs were collected from
the supernatant by centrifugation at 105000 g (90 min, 4 °C) and
re-suspended in phosphate-buffered saline, pH 7.5. MVs were
quantiﬁed based on protein content using the Bradford assay (Protein
Assay Reagent, Bio-Rad, UK) with BSA as a standard protein.
4.4. Aggrecanase assay
Aggrecan (500 nM, 50 μg in 50 μl assay volume) was incubated
with MVs or ADAMTS-5 in 50 mM Tris–HCl, pH 7.5, 100 mM NaCl,
10 mM CaCl2, and 0.05% Brij 35 at 37 °C. For inhibitor analysis,
ADAMTSs or MVs were pre-incubated with inhibitors (1 h, 37 °C)
before addition of aggrecan. Samples were prepared for immuno-
blotting by treatment with chondroitinase ABC and keratanase
(Seikagaku, Japan) (0.01 units each, 16 h, 37 °C) and precipitation
with acetone (5 volumes, −20 °C, 18 h). Degradation was visualised
using antibodies recognising degraded aggrecan fragments as
before (Troeberg et al., 2008). The 2-B-6 antibody recognises
chondroitinase-treated aggrecan (Caterson et al., 1985); anti-
374ARGSV recognises aggrecan cleaved at NITEGE373–374ARGSV
(Hughes et al., 1995), anti-GELE1480 recognises aggrecan cleaved at
GELE1480–1481GRGT (Kashiwagi et al., 2004) and anti-1772AGEG
recognises aggrecan cleaved at TAQE1771–1772AGEG (Troeberg et al.,
2008). Blots were quantiﬁed using ImageJ software.
4.5. RT-PCR
Adamts expression was evaluated by RT-PCR of the total RNA
extracted from G26/24 and mouse embryonic ﬁbroblasts (MEF) using a
QIAamp RNA Blood Mini Kit (Qiagen Ltd, UK). Primers for Adamts1
ampliﬁcation were: 5′-CAGGAAGCATAAGGAAGAAG-3′ (forward) and
5′-GCACAGTGCTTAGCATCATCA-3′ (reverse), for Adamts4: 5′-ATGTGGG-
CACAGTGTGTGAT-3′ (forward) and 5′-CAAGGTGAGTGCTTCGTCTG-3′
(reverse), and for Adamts5: 5′-GGCATCATTCATGTGACACC-3′ (forward)
and 5′-CGAGTACTCAGGCCCAAATG-3′ (reverse) (Stanton et al., 2005).
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